FLUNISOLIDE

Search structure
Trade Names:
Synonyms:
Status: Approved (1981)
Entry Type: Small molecule
Molecule Category: Parent
ATC: R01AD04
UNII: 78M02AA8KF

Structure
InChI Key XSFJVAJPIHIPKU-XWCQMRHXSA-N
Smile CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
InChI
InChI=1S/C24H31FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h5-7,13-14,16-17,19-20,26,28H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C24H31FO6
Molecular Weight 434.5
AlogP 2.27
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 2.0
Polar Surface Area 93.06
Molecular species NEUTRAL
Aromatic Rings 0.0
Heavy Atoms 31.0

Pharmacology

Action Mechanism of Action Reference
AGONIST Glucocorticoid receptor agonist ISBN DailyMed
Primary Target
Glucocorticoid receptor
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - 55

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Asthma 4 D001249 FDA
Rhinitis, Allergic, Perennial 3 D012221 ClinicalTrials

Related Entries

MCS

Scaffolds

Side Effects from Label

Side effects Relative Frequency (%) Labels
Gastrointestinal disorders Pharyngitis 17.5
Gastrointestinal disorders Pharyngitis 16.8
Gastrointestinal disorders Pharyngitis 16.6
Infections and infestations Rhinitis 15.7
Nervous system disorders Headache 13.8
Gastrointestinal disorders Pharyngitis
Nervous system disorders Headache
Infections and infestations Rhinitis
Nervous system disorders Headache 9.0
Infections and infestations Rhinitis 9.0
Nervous system disorders Headache 8.8
Infections and infestations Sinusitis 8.8
Respiratory, thoracic and mediastinal disorders Cough 8.5
Respiratory, thoracic and mediastinal disorders Cough
Infections and infestations Sinusitis 7.4
Investigations Body temperature increased 6.9
Respiratory, thoracic and mediastinal disorders Cough 5.5
Infections and infestations Sinusitis
Investigations Body temperature increased
Immune system disorders Hypersensitivity 4.6
General disorders and administration site conditions Pain 4.6
Gastrointestinal disorders Vomiting 4.6
Immune system disorders Hypersensitivity 4.4
Immune system disorders Hypersensitivity 4.2
Gastrointestinal disorders Vomiting 4.2
Infections and infestations Sinusitis 4.1
Gastrointestinal disorders Vomiting
Investigations Body temperature increased 3.7
Skin and subcutaneous tissue disorders Dermatitis 3.7
Infections and infestations Infection 3.7
Injury, poisoning and procedural complications Injury 3.7
Skin and subcutaneous tissue disorders Rash 3.7
General disorders and administration site conditions Pain
Gastrointestinal disorders Dyspepsia 3.5
Injury, poisoning and procedural complications Injury 3.5
Infections and infestations Rhinitis 3.5
Infections and infestations Urinary tract infection 3.5
Musculoskeletal and connective tissue disorders Back pain 3.2
Skin and subcutaneous tissue disorders Dermatitis
Gastrointestinal disorders Dyspepsia 3.2
Respiratory, thoracic and mediastinal disorders Epistaxis 3.2
Skin and subcutaneous tissue disorders Rash
Skin and subcutaneous tissue disorders Dermatitis 2.6
General disorders and administration site conditions Pain 2.6
Skin and subcutaneous tissue disorders Rash 2.6
Musculoskeletal and connective tissue disorders Back pain
Immune system disorders Hypersensitivity
Injury, poisoning and procedural complications Injury
Gastrointestinal disorders Dyspepsia 2.1
Musculoskeletal and connective tissue disorders Back pain 1.8
Respiratory, thoracic and mediastinal disorders Cough 1.8
Skin and subcutaneous tissue disorders Dermatitis 1.8
General disorders and administration site conditions Pain 1.8
Skin and subcutaneous tissue disorders Rash 1.8
Gastrointestinal disorders Dyspepsia
Infections and infestations Urinary tract infection 1.1
Investigations Body temperature increased 0.9
Respiratory, thoracic and mediastinal disorders Epistaxis
Respiratory, thoracic and mediastinal disorders Epistaxis 0.9
Infections and infestations Infection
Infections and infestations Infection 0.9
Infections and infestations Urinary tract infection 0.9
Musculoskeletal and connective tissue disorders Back pain 0.5
Infections and infestations Urinary tract infection

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Respiratory, thoracic and mediastinal disorders
27.08
General disorders and administration site conditions
14.58
Injury, poisoning and procedural complications
9.72
Nervous system disorders
8.33
Gastrointestinal disorders
6.6
Immune system disorders
6.6
Cardiac disorders
4.51
Skin and subcutaneous tissue disorders
4.17
Eye disorders
3.12
Product issues
3.12
Psychiatric disorders
2.43
Vascular disorders
2.43
Ear and labyrinth disorders
2.08
Infections and infestations
2.08
Musculoskeletal and connective tissue disorders
2.08

Cross References

Resources Reference
CAS NUMBER 3385-03-3
ChEBI 5106
ChEMBL CHEMBL1512
DrugBank DB00180
DrugCentral 1201
EPA CompTox DTXSID1045534
FDA SRS 78M02AA8KF
Human Metabolome Database HMDB0014326
Guide to Pharmacology 7076
KEGG C07005
PharmGKB PA449661
PubChem 11954221
SureChEMBL SCHEMBL4351
ZINC ZINC000004097305
CONTENTS